Outlook Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 24
- Market Cap
- $176.7M
- Introduction
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06190093
- Locations
- 🇺🇸
Clinical Site, Silverdale, Washington, United States
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05112861
- Locations
- 🇺🇸
Clinical Site, Chambersburg, Pennsylvania, United States
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04516278
- Locations
- 🇺🇸
Clinical Site, Willow Park, Texas, United States
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT03844074
- Locations
- 🇦🇺
Clinical Site, Glen Waverley, Victoria, Australia
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03834753
- Locations
- 🇺🇸
Clinical Site, Madison, Wisconsin, United States
© Copyright 2024. All Rights Reserved by MedPath